Biphasic papillary and lobular breast carcinoma with PIK3CA and IDH1 mutations

Diagnostic Molecular Pathology

Volumn 21, Issue 4, 2012, Pages 221-224

  Ang, Daphne ^a,b   Vansandt, Amanda M ^a   Beadling, Carol ^b   Warrick, Andrea ^b   West, Robert B ^c   Corless, Christopher L ^a,b   Troxell, Megan L ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma; IDH1; lobular carcinoma; papillary carcinoma; PIK3CA

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; MYOSIN HEAVY CHAIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P63;

AGED; ARTICLE; BREAST ABSCESS; BREAST BIOPSY; BREAST CARCINOMA; BREAST DISCHARGE; BREAST DUCT; CANCER SURGERY; CASE REPORT; CLONAL EVOLUTION; EXON; FEMALE; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGATION; LYMPH NODE DISSECTION; MASTECTOMY; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; PAPILLARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TISSUE MICROARRAY; TREATMENT DURATION;

AGED; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOCITRATE DEHYDROGENASE; LYMPH NODES; MASTECTOMY; NEOPLASMS, MULTIPLE PRIMARY; PHOSPHATIDYLINOSITOL 3-KINASES; POINT MUTATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84870241871     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31826ddbd1     Document Type: Article

References (24)

1. van Bogaert LJ. Recent progress in the histological typing of human breast tumours. Diagn Histopathol. 1981;4:349-353. (Pubitemid 12247286)
2. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009; 6:718-730.
3. Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667-2675. (Pubitemid 39574720)
4. Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol. 2011;18:255-267.
5. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378: 1812-1823.
6. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141-150.
7. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn. 2011;13: 504-513.
8. Troxell ML, Brunner AL, Neff T, et al. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. Mod Pathol. 2012;25:930-937.
9. Webster JA, Beck AH, Sharma M, et al. Variations in stromal signatures in breast and colorectal cancer metastases. J Pathol. 2010;222:158-165.
10. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94: 455-459. (Pubitemid 43289745)
11. Castaneda CA, Cortes-Funes H, Gomez HL, et al. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 2010;29:751-759.
12. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-562.
13. Troxell ML. PIK3CA/AKT1 mutations in breast carcinoma: a comprehensive review of experimental and clinical studies. J Clin Exp Pathol. 2012. In press. doi:10.4172/2161-0681.S1-002.
14. Troxell ML, Levine J, Beadling C, et al. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol. 2010;23:27-37.
15. Duprez R, Wilkerson PM, Lacroix-Triki M, et al. Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol. 2012;226:427-441.
16. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol. 2006;208:350-355. (Pubitemid 43210521)
17. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
18. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125:353-355.
19. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30:7-11.
20. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339-344.
21. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932-941.
22. Fathi AT, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012;2012:469592.
23. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70:8981-8987.
24. Neyns B, Sadones J, Chaskis C, et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol. 2011;103:491-501.